Top 10 Biotech Stocks To Own Right Now

Financial Gravity Companies Inc. raised its stake in shares of Grifols (NASDAQ:GRFS) by 264.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 13,862 shares of the biotechnology company’s stock after purchasing an additional 10,054 shares during the quarter. Financial Gravity Companies Inc.’s holdings in Grifols were worth $282,000 as of its most recent filing with the SEC.

Several other large investors also recently bought and sold shares of GRFS. Dean Capital Investments Management LLC bought a new position in shares of Grifols during the 4th quarter worth about $214,000. Pitcairn Co. bought a new stake in Grifols in the fourth quarter valued at about $228,000. Lenox Wealth Management Inc. increased its stake in Grifols by 93.2% in the fourth quarter. Lenox Wealth Management Inc. now owns 11,460 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 5,529 shares during the period. Commerce Bank bought a new stake in Grifols in the first quarter valued at about $313,000. Finally, Dowling & Yahnke LLC bought a new stake in Grifols in the fourth quarter valued at about $327,000. Institutional investors own 22.35% of the company’s stock.

Top 10 Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Pfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) looked to be in a two-horse race to develop TTR amyloidosis (ATTR) drugs. Alnylam recently got its drug Onpattro approved, while Ionis Pharmaceuticals and its marketing partner Akcea Therapeutics (NASDAQ:AKCA) should hear about Tegsedi by Oct. 6. Tegsedi was approved in the EU last month.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Northern Trust Corp lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 492,768 shares of the biopharmaceutical company’s stock after purchasing an additional 20,992 shares during the period. Northern Trust Corp owned about 0.49% of Alnylam Pharmaceuticals worth $48,533,000 at the end of the most recent quarter.

Top 10 Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Brian Orelli]

    Data source: Ionis Pharmaceuticals.

    What happened with Ionis Pharmaceuticals this quarter?
    Royalties from Biogen (NASDAQ:BIIB) for sales of Spinraza came in at $57 million, more than double the year-ago quarter. The rest of the revenue comes from research and development revenue, which can vary from quarter to quarter due to milestone payments. In July, Ionis’ marketing partner Akcea Therapeutics (NASDAQ:AKCA) received EU approval for Tegsedi, the brand name for inotersen that treats hereditary transthyretin amyloidosis (ATTR). Earlier this month, Akcea licensed the Latin American rights to Tegsedi and Waylivra, which treats diseases with high lipid levels, to PTC Therapeutics (NASDAQ:PTCT); Ionis gets 60% of the milestone and royalty payments from PTC Therapeutics for Tegsedi and 50% of the payments for Waylivra. The larger loss came from an increase in R&D expenses, as Ionis and Akcea — which is still included in Ionis’ profit-loss statement because Ionis owns a majority stake — continue to advance Ionis’ pipeline. Selling, general, and administrative costs also increased as Akcea prepares to launch Tegsedi and Waylivra. Ionis’ balance sheet can certainly absorb the quarterly loss; the biotech ended the quarter with $2 billion in the bank thanks to its latest deal with Biogen, which is plenty to get by as it waits for revenue to start rolling in.

    Image source: Getty Images.

  • [By Chris Lange]

    Biogen Inc.’s (NASDAQ: BIIB) second-quarter report is scheduled for Tuesday before the markets open. The consensus estimates are $5.24 in earnings per share (EPS) on $3.26 billion in revenue. The shares ended the week trading at $357.56. The consensus price target is $367.08, and the 52-week trading range is $249.17 to $370.57.

  • [By George Budwell]

    Not surprisingly, biotech titans Celgene (NASDAQ:CELG) and Biogen (NASDAQ:BIIB) are among the leaders in this ongoing biopharma revolution. So, with that theme in mind, let’s attempt to gauge which of these top biotechs is the more attractive long-term buy for investors right now.

  • [By Logan Wallace]

    Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, April 24th. The biotechnology company reported $6.05 earnings per share for the quarter, topping the consensus estimate of $5.93 by $0.12. The firm had revenue of $3.13 billion for the quarter, compared to analyst estimates of $3.15 billion. Biogen had a net margin of 23.54% and a return on equity of 37.64%. Biogen’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.20 earnings per share. research analysts anticipate that Biogen will post 23.94 earnings per share for the current year.

  • [By Sean Williams]

    Of course, my “bet against all Alzheimer’s drugs” thesis took a bit of a hit last week when biotech blue-chip Biogen (NASDAQ:BIIB), which is working alongside partner Eisai (NASDAQOTH:ESALY), reported positive mid-stage data on blockbuster hopeful BAN2401.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) decreased slightly to 3.09 million shares from the previous 3.15 million. The stock recently traded at $344.57, within a 52-week range of $249.17 to $388.67.

Top 10 Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Motley Fool Transcribers]

    Arqule Inc  (NASDAQ:ARQL)Q4 2018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 10 Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Brian Feroldi]

    The study in question is called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum’s drug Rolontis when compared to Amgen’s (NASDAQ:AMGN) megablockbuster drug Neulasta in patients with early-stage breast cancer.

  • [By Trey Thoelcke]

    Amgen Inc.’s (NASDAQ: AMGN) death cross also occurred this week, after the gap between the two averages had been closing since last October. As with some of its peers, short interest in this biotech stock has waned recently. Amgen shares are down more than 4% year to date. Yet, here too analysts recommend buying shares.

  • [By Logan Wallace]

    Navellier & Associates Inc lifted its holdings in Amgen, Inc. (NASDAQ:AMGN) by 1.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,176 shares of the medical research company’s stock after purchasing an additional 353 shares during the period. Navellier & Associates Inc’s holdings in Amgen were worth $4,278,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Philadelphia Trust Co. decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 8.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 74,676 shares of the medical research company’s stock after selling 6,501 shares during the quarter. Amgen makes up 1.2% of Philadelphia Trust Co.’s portfolio, making the stock its 22nd biggest position. Philadelphia Trust Co.’s holdings in Amgen were worth $13,784,000 as of its most recent SEC filing.

  • [By Keith Speights]

    The way to determine where a puck is going to be requires evaluating its direction and speed. I used a similar approach to identify five stocks with fast-growing dividends: Boeing (NYSE:BA), Amgen (NASDAQ:AMGN), CVS Health (NYSE:CVS), Texas Instruments (NASDAQ:TXN), and AbbVie (NYSE:ABBV). Here’s why these stocks could be great picks for dividend-seeking investors.

Leave a Reply

Your email address will not be published. Required fields are marked *